George A. Scangos is one of the most successful biotech CEOs in the world, leading the way to a new era of healthcare innovation and scientific breakthroughs. Scangos has an impressive resume, having held top positions with some of the leading companies in the industry. He is credited with taking biotech companies to greater heights, and with helping to bring the life sciences industry to the forefront of the global business stage.
George Scangos grew up in the United States and attended the University of California at San Francisco, graduating with a degree in biochemistry. From there, he went on to complete a PhD in cell biology at Stanford University in 1987. After his studies, Scangos worked at Merck & Co, where he led the development of several important new drugs.
Scangos then joined Biogen Inc in 1989 as Vice President of Molecular Biology. Here, Scangos was responsible for leading research teams and putting together a portfolio of drugs for treatment of diseases such as multiple sclerosis and hemophilia. In 1997, he moved to the position of Chief Scientific Officer, and then President and CEO in 2003. During his tenure at Biogen, Scangos successfully led the company through a period of rapid growth, rising share prices and a number of key acquisitions, which helped catapult the company to greater heights.
In 2010, Scangos moved to his current role as CEO of the global biotechnology company, Celgene Corporation. Under his leadership, the company has grown significantly in size, as well as in share price. Scangos has been responsible for overseeing the company’s expansion and acquisition of several new companies, including Quanticel Pharmaceuticals and Juno Therapeutics.
Scangos has also led Celgene to become a major player in the biotechnology industry, driving innovation and scientific breakthroughs, as well as developing customer focused business models designed to foster long-term growth and success. Scangos has worked tirelessly to lead Celgene to become a global biotech leader, and has achieved success through his prudent risk-taking and expansive vision.
One of Scangos’s most successful strategies was his decision to diversify Celgene’s product portfolio beyond the company’s main focus on cancer treatments. This expansion into other treatment areas has allowed Celgene to tap into new markets, generate higher sales and profits, and further expand the company’s reach in the global market. Scangos’s vision for the future of Celgene is to advance treatments for a wide range of diseases, including Alzheimer’s, multiple sclerosis, inflammatory bowel disease and more.
George A. Scangos is an accomplished leader, scientist and businessman. He has helped to lead Celgene Corporation to new heights and has positioned the company to become a major player in the biotechnology industry. His visionary approach to the life sciences represents a new era of healthcare and is helping to bring the life sciences industry to the forefront of the global business stage.
